This research study plans to learn more about the safety and tolerability of psychedelic administration (psilocybin) in healthy older adults. This study also plans to learn more about how psilocybin is processed in the bodies of healthy older adults as well as psychedelic experiences and well-being related to psilocybin. Participants will receive 2 escalating doses of psilocybin (medication visit) 30 days apart in conjunction with preparation and integration facilitation sessions. Blood samples & EKGs will be collected throughout the medication visits. Participants will be required to attend a combination of in-person and remote study visits throughout the study (16 study visits across 3.5 months). The initial enrollment visit for the study will include: - Medical history and physical - Electrocardiogram (EKG) - Safety and laboratory assessments including blood and urine testing - Psychological and cognitive assessments

Who can Participate

- Age 65-85 years - Generally healthy - Have a support person who can take you home after your medication visits - Ability to consent

Study ID